706785-93-5
Chemical Structure
L803-mts
Synonym(s): Myristoylated L 803; GSK-3β Inhibitor XIII
- CAS No.: 706785-93-5
- Formula:C66H109N14O21P
- Molecular Weight:1465.63
IUPAC Name: (S)-5-(((S)-1-((S)-2-((S)-2-(((S)-1-((S)-2-((S)-2-(((S)-5-amino-1-(((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-1-oxo-3-(phosphonooxy)propan-2-yl)amino)-1,5-dioxopentan-2-yl)carbamoyl)pyrrolidine-1-carbonyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)carbamoyl)pyrrolidine-1-carbonyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)amino)-4-((S)-6-amino-2-(2-tetradecanamidoacetamido)hexanamido)-5-oxopentanoic acid
InChIKey: JLHWBVQBEGDSEZ-LFOOZZFTSA-N
SMILES: O=C([C@H](CCC1)N1C([C@H](C)NC([C@H](CCC2)N2C([C@H](CCC3)N3C([C@H](C)NC([C@H](CCC(O)=O)NC([C@H](CCCCN)NC(CNC(CCCCCCCCCCCCC)=O)=O)=O)=O)=O)=O)=O)=O)N(CCC4)[C@@H]4C(N[C@@H](CCC(N)=O)C(N[C@@H](CO[P](O)(O)=O)C(N(CCC5)[C@@H]5C(O)=O)=O)=O)=O
Biological Activity: L803-mts (Myristoylated L 803) is a selective and substrate-competitive GSK-3 peptide inhibitor (IC50: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
L803-mts | 99.98% | L803-mts (Myristoylated L 803) is a selective and substrate-competitive GSK-3 peptide inhibitor (IC50: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kaidanovich-Beilin O, et al. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry. 2004 Apr 15;55(8):781-4. [Content Brief]
- [2]. Avrahami L, et al. Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J Biol Chem. 2013 Jan 11;288(2):1295-306. [Content Brief]
